Clinical Trial Update: Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating brentuximab vedotin for steroid-resistant acute graft-versus-host disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease Acute

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Conditions: Graft Versus Host Disease | Phase 2 | Status: WITHDRAWN